Personalized and Precision Medicine Journal

Abstract IntroductionLung cancer is the prevailing form of cancer globally, with a significant fatality rate among both males and females. Lung cancer is the third most frequent type of cancer in Iran, and it is becoming more common all the time. Patients are frequently diagnosed in the advanced stages of the disease, which contributes to the high death rate. Therefore, the ability to identify molecular markers is essential for both early diagnosis and the choice of conventional treatment for lung cancer. Numerous genetic variations have been found to be strongly linked to the development of lung cancer, according to studies. The aim of this work is to look into the genes that contribute to the development of lung cancer.
Materials and methods: The present review was authored using search terms related to lung cancer, key genes, clinical biomarkers, and early diagnosis that were found on PubMed, NCBI, Scopus, Science Direct, and Google Scholar.
Findings: Since the EGFR, KRAS, BRAF, and TP53 genes are the most significant and involved in the development of lung cancer, finding mutations in these genes can be a valuable clinical diagnostic for lung cancer diagnosis and therapy.
Discussion and conclusion: With an emphasis on personalized medicine, the identification of genes linked to lung cancer may be utilized as clinical biomarkers for the disease's early diagnosis and effective treatment. The state of targeted lung cancer therapy and early detection techniques may be enhanced by molecular biomarkers. In the field of personalized medicine, identifying the genes linked to lung cancer as clinical biomarkers for early diagnosis and assessing treatment response to select a targeted treatment can be crucial in streamlining the therapeutic process, improving treatment response, lowering mortality, and lessening the material and spiritual harm this illness causes.